|
Sep 11
|
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
Sep 11
|
Why Shares of Crinetics Pharmaceuticals Are Jumping Monday
|
|
Sep 11
|
Crinetics shares surge after "positive" hormonal disorder drug trial results
|
|
Sep 10
|
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
|
|
Aug 10
|
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 8
|
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|